Home›Search›CNS Drugs

CNS Drugs

ADIS INT LTD · Switzerland · Est. 1952

ISSN1179-1934

SJR Q1✓ WOS SCIE✓ Scopus / SJR

/ 100

High Trust

PubScope credibility score from verifiable indexing & ethics signals

Score Breakdown

◆ WoS flagship (SCIE/SSCI/AHCI)78

✓ Corroboration (3 more)+18

Total96

Level data: Norwegian Register (HK-dir), NLOD 2.0. · Third-party records · how this is calculated · Report an error →

⚡ Speed vs Prestige

How does this journal balance review speed with impact level?

147

days submission → published

measured · last 9 articles · accept 112d

SJR Rank

Top 25% in field

Impact Factor & Quartile · Web of Science (JCR)

✓ Indexed in the Web of Science Core Collection (SCIE) — Clarivate publishes an official Journal Impact Factor and JCR quartile for this journal.

See the official Impact Factor & quartile on the journal’s page ↗

The Impact Factor & JCR quartile are licensed by Clarivate — we link you to the official source instead of reprinting a number that can go out of date. Open metrics below: SCImago Q1. Source: Clarivate Journal Citation Reports.

SJR Scorei

2.161

H-Indexi

162

CiteScore

View ↗

Scopus metric · on the journal’s page

SNIPi

2.233

Total Worksi

2,925

Total Citationsi

136,582

2yr Mean Citednessi

5.90

Open Impact Factor alternative

Aims & Scope

CNS Drugs provides researchers and healthcare professionals with essential information on the most important aspects of drug therapies used for the management of neurological and psychiatric disorders. Via a program of reviews and original research articles, the journal addresses major issues relating to drug therapy of these disorders, including the pharmacology, efficacy and adverse effects of the major classes of drugs; information on newly developed drugs and drug classes; the therapeutic implications of latest research into the aetiology of neurological and psychiatric disorders; and the practical management of specific clinical situations.

General Information

Country / RegionSwitzerland

Primary LanguageEnglish

1st Year Published1952

FrequencyMonthly

StatusActive (last: 2026)

Total Publications2,925

Publisher OrgAdis, Springer Healthcare

Visit Journal Website

Submission Info

Peer Review—

Review Time—

Acceptance Rate—

OA License—

OA Rate—

Ethics & Quality

COPE Member✗ No

OASPA Member✗ No

Not on Predatory Lists✓ Yes

📦 Long-term Preservation

CLOCKSSPortico

Think.Check.Submit Compliance

thinkchecksubmit.org

7/12 · 58%

✅

Do you know the journal / publisher?

ADIS INT LTD

✅

Does the journal have a website?

✓ Linked

✅

Is the ISSN verified?

1179-1934

✅

Indexed in a trusted database?

WoS, Scopus

❌

Peer review process documented?

N/A

❌

Follows ethical publishing standards (COPE)?

N/A

❌

APC fees clearly disclosed?

N/A

✅

Not on predatory/blacklists?

✓ Clean

✅

Long-term digital preservation?

CLOCKSS, Portico

❌

Plagiarism detection in place?

N/A

❌

Listed in DOAJ (verified OA)?

N/A

✅

Primary language documented?

English

Based on the Think.Check.Submit framework by DOAJ, COPE & OASPA. All data from verified open sources.

Publication & Citation Trend

Articles published

Citations received

4.5k

2019

3.8k

2020

109

2021

3.1k

2022

1.4k

2023

1.1k

2024

110

496

2025

2026

Source: OpenAlex · Each year’s green bar = citations earned by that year’s papers, counted to date — so recent years look lower simply because their papers haven’t had time to be cited yet.

SJR Quartile by Discipline

Scimago ranks this journal separately in each subject category — its quartile can differ by discipline.

Neurology (clinical)Q1

Pharmacology (medical)Q1

Psychiatry and Mental HealthQ1

Subject Classification

Web of Science Categories

Clinical NeurologyPharmacology & PharmacyPsychiatry

Scopus Categories

Pharmacology (medical)Neurology (clinical)Psychiatry and Mental Health

Research Topics (OpenAlex)

Schizophrenia research and treatmentEpilepsy research and treatmentTreatment of Major DepressionPharmacological Effects and Toxicity StudiesBipolar Disorder and TreatmentNeurotransmitter Receptor Influence on BehaviorNeuroscience and Neuropharmacology ResearchParkinson's Disease Mechanisms and TreatmentsAttention Deficit Hyperactivity DisorderMultiple Sclerosis Research Studies

Frequently asked questions about CNS Drugs

Is CNS Drugs a predatory journal?

PubScope has no integrity flags on record for CNS Drugs: it is indexed in Web of Science, Scopus, and is not on DOAJ's withdrawn list. Its PubScope Trust Score is 96/100. Indexing is a transparency signal, not a guarantee — always confirm fit and policies before submitting.

What is the impact factor of CNS Drugs?

CNS Drugs is indexed in the Web of Science Core Collection, so Clarivate publishes an official Journal Impact Factor for it (since the 2023 Journal Citation Reports, every Core Collection journal — including Arts & Humanities and Emerging Sources titles — receives one). PubScope links to Clarivate's official source rather than reprinting the number, which can be out of date. Its open 2-year mean citedness is 5.90.

Is CNS Drugs indexed in Scopus and Web of Science?

CNS Drugs is indexed in Web of Science, Scopus.